1. Acute Cerebellar Ataxia Associated with Anti-glutamic Acid Decarboxylase Antibodies Mimicking Miller Fisher Syndrome
- Author
-
Hideto Nakajima, Takafumi Hosokawa, Fumiharu Kimura, Yoshitsugu Nakamura, Shimon Ishida, and Kazushi Yamane
- Subjects
Gait Ataxia ,Male ,0301 basic medicine ,corticosteroid ,endocrine system ,medicine.medical_specialty ,Ataxia ,Cerebellar Ataxia ,endocrine system diseases ,medicine.drug_class ,Glutamate decarboxylase ,Case Report ,acute onset ,Diagnosis, Differential ,03 medical and health sciences ,0302 clinical medicine ,Cerebrospinal fluid ,Internal medicine ,Diplopia ,Internal Medicine ,medicine ,Humans ,Autoantibodies ,Miller Fisher Syndrome ,Ophthalmoplegia ,Cerebellar ataxia ,Glutamate Decarboxylase ,business.industry ,ataxia ,Therapeutic effect ,General Medicine ,Middle Aged ,030104 developmental biology ,Endocrinology ,anti-GAD ,Prednisolone ,Corticosteroid ,medicine.symptom ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
We herein report the case of a 53-year-old man with cerebellar ataxia with anti-glutamic acid decarboxylase antibody (GAD-Ab) who mimicked Miller Fisher syndrome (MFS). He developed ophthalmoplegia, diplopia, and gait ataxia for one week. The serum and cerebrospinal fluid GAD-Ab titers were greatly increased, and the GAD-Ab index suggesting intrathecal antibody synthesis was elevated, while GQ1b-Ab was negative. After steroid pulse therapy and following prednisolone, his symptoms dramatically improved over the course of 11 months with the simultaneous decline of GAD-Ab titers. This case indicates that cerebellar ataxia with GAD-Ab can present with acute neurological findings mimicking MFS, and that steroid therapy has an excellent therapeutic effect.
- Published
- 2018
- Full Text
- View/download PDF